Literature DB >> 27289228

Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Irma Convertino1, Alice Capogrosso Sansone1, Alessandra Marino1, Maria T Galiulo1, Stefania Mantarro1, Luca Antonioli1, Matteo Fornai1, Corrado Blandizzi1,2, Marco Tuccori3.   

Abstract

Exposure to drugs during pregnancy has the potential to harm offspring. Teratogenic effects are the most feared adverse outcomes in newborns; however, a wide spectrum of less known, usually reversible and often acute, neonatal adverse events can also occur due to drug intake by mothers during pregnancy, particularly in close proximity to delivery. This narrative review is aimed at the description of drugs and drug classes for which licit maternal use in the predelivery period has been associated with neonatal non-teratogenic disorders. For each drug class, epidemiology, clinical features, biological mechanism and management of these adverse reactions have been discussed in detail. Although these adverse reactions have been described mainly for substances used illicitly for recreational purposes, several prescription drugs have also been involved; these include mainly psychotropic medications such as opioids, antidepressants, antiepileptics and antipsychotics. These effects can be partly explained by withdrawal syndromes (defined also as 'neonatal abstinence syndrome') caused by the delivery-related discontinuation of the drug disposition from the mother to the fetus, with symptoms that may include feeding disorders, tremors, irritability, hypotonia/hypertonia, vomiting and persistent crying, occurring a few hours to 1 month after delivery. Otherwise, neonatal neurological and behavioral effects can also be caused by a residual pharmacological effect due to an accumulation of the drug in the blood and tissues of the newborn, with various symptoms related to the toxic effects of the specific drug class, usually developing a few hours after birth. With few exceptions, validated protocols for the assessment and management of withdrawal or residual pharmacological effects of these drugs in neonates are often lacking or incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27289228     DOI: 10.1007/s40264-016-0435-8

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  300 in total

1.  Neonate characteristics after maternal use of antidepressants in late pregnancy.

Authors:  Bengt Källén
Journal:  Arch Pediatr Adolesc Med       Date:  2004-04

2.  Neonatal withdrawal syndrome: reaching epidemic proportions across the globe.

Authors:  Karel Allegaert; John N van den Anker
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2015-10-19       Impact factor: 5.747

3.  Outcome of infants exposed to olanzapine during breastfeeding.

Authors:  Oded Gilad; Paul Merlob; Bracha Stahl; Gil Klinger
Journal:  Breastfeed Med       Date:  2010-10-29       Impact factor: 1.817

4.  Neonatal alprazolam withdrawal--possible effects of breast feeding.

Authors:  P O Anderson; G G McGuire
Journal:  DICP       Date:  1989 Jul-Aug

5.  Valproic acid transfer across human placental cotyledon during dual perfusion in vitro.

Authors:  Anna Semczuk-Sikora; Stanislaw Czuczwar; Andrzej Semczuk; Anna Kwasniewska; Marian Semczuk
Journal:  Ann Agric Environ Med       Date:  2010       Impact factor: 1.447

6.  Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy.

Authors:  Raphaël Serreau; Meriem Komiha; Florence Blanc; François Guillot; Evelyne Jacqz-Aigrain
Journal:  Reprod Toxicol       Date:  2005-04-15       Impact factor: 3.143

7.  Fetal phenytoin exposure, hypoplastic nails, and jitteriness.

Authors:  S W D'Souza; I G Robertson; D Donnai; G Mawer
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

Review 8.  Use of buprenorphine in pregnancy: patient management and effects on the neonate.

Authors:  Rolley E Johnson; Hendrée E Jones; Gabriele Fischer
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

Review 9.  Special considerations in treating bipolar disorder in women.

Authors:  Vivien K Burt; Natalie Rasgon
Journal:  Bipolar Disord       Date:  2004-02       Impact factor: 6.744

10.  [Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].

Authors:  S Koch; I Göpfert-Geyer; E Jäger-Roman; S Jakob; H Huth; A Hartmann; D Rating; H Helge
Journal:  Dtsch Med Wochenschr       Date:  1983-02-18       Impact factor: 0.628

View more
  3 in total

1.  Capturing the statewide incidence of neonatal abstinence syndrome in real time: the West Virginia experience.

Authors:  Amna Umer; Sean Loudin; Stefan Maxwell; Christa Lilly; Meagan E Stabler; Lesley Cottrell; Candice Hamilton; Janine Breyel; Christina Mullins; Collin John
Journal:  Pediatr Res       Date:  2018-10-04       Impact factor: 3.756

2.  An advanced human in vitro co-culture model for translocation studies across the placental barrier.

Authors:  Leonie Aengenheister; Kerda Keevend; Carina Muoth; René Schönenberger; Liliane Diener; Peter Wick; Tina Buerki-Thurnherr
Journal:  Sci Rep       Date:  2018-03-29       Impact factor: 4.379

3.  Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: a case report.

Authors:  Jumpei Saito; Yoshiyuki Tachibana; Yuka Sano Wada; Naho Yakuwa; Hiroyo Kawasaki; Tomo Suzuki; Haruhiko Sago; Akimasa Yamatani; Atsuko Murashima
Journal:  J Pharm Health Care Sci       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.